Published 6 days ago • loading... • Updated 6 days ago

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

XPOVIO® is now the first and only approved XPO1 inhibitor in Indonesia, as stated by the Indonesia National Agency of Drug and Food Control .
The Indonesia National Agency of Drug and Food Control approved a New Drug Application for XPOVIO® for three treatment indications, according to the announcement.
XPOVIO® has been approved for multiple indications in ten APAC markets, including Thailand, Malaysia, China, Taiwan, and South Korea, as per the report.
Antengene aims to expand XPOVIO®'s indications and develop combination regimens for other cancers, enhancing healthcare in the ASEAN region.

Insights by Ground AI

Does this summary seem wrong?

51 Articles

All

Left

Center

Right

Tioga Publishing

+49 Reposted by 49 other sources

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

XPOVIO® is the first and only approved XPO1 inhibitor in Indonesia.

6 days ago·Pennsylvania, United States

Read Full Article

Laotian Times

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene’s Commercial Presence in APAC

– XPOVIO® is the first and only approved XPO1 inhibitor in Indonesia. – From the second half of 2024 to now, XPOVIO® was successively approved in Thailand, Malaysia and Indonesia, significantly expanding Antengene’s commercial presence in APAC. To date, XPOVIO® has been approved for multiple indications in ten markets across the APAC region. – XPOVIO® has been […]

6 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year